Hydrochloric Acid → N-[(5-hydroxy-6-(1-methylethyl)-2-{[2'-(methyloxy)-2-biphenylyl]methyl}-3-oxo-2,3-dihydro-4-pyridazinyl)carbonyl]glycine

HRID 2046291Notes

Reaction equation

HRID 2046291 reaction equation
Br[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][C:3]=1[CH2:8][N:9]1[C:14](=[O:15])[C:13]([C:16]([NH:18][CH2:19][C:20]([OH:22])=[O:21])=[O:17])=[C:12]([OH:23])[C:11]([CH:24]([CH3:26])[CH3:25])=[N:10]1.[CH3:27][O:28][C:29]1[CH:34]=[CH:33][CH:32]=[CH:31][C:30]=1B(O)O.C(=O)([O-])[O-].[K+].[K+].Cl>O1CCOCC1.O.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[OH:23][C:12]1[C:11]([CH:24]([CH3:26])[CH3:25])=[N:10][N:9]([CH2:8][C:3]2[CH:4]=[CH:5][CH:6]=[CH:7][C:2]=2[C:30]2[CH:31]=[CH:32][CH:33]=[CH:34][C:29]=2[O:28][CH3:27])[C:14](=[O:15])[C:13]=1[C:16]([NH:18][CH2:19][C:20]([OH:22])=[O:21])=[O:17]

Participants

8

Reactant 4

HCID 313Hydrochloric AcidHCID 11430Potassium CarbonateHCID 27339582-Methoxyphenylboronic acidHCID 54739212N-{[2-[(2-Bromophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine

Product 1

HCID 54739197N-[(5-hydroxy-6-(1-methylethyl)-2-{[2'-(methyloxy)-2-biphenylyl]methyl}-3-oxo-2,3-dihydro-4-pyridazinyl)carbonyl]glycineYield 49.7%

Reagents, catalysts & solvents 3

HCID 178418397HCID 178418397, compoundCatalystHCID 962WaterSolvent2×HCID 312751,4-DioxaneSolvent

Procedure

To a 5 ml microwave tube was added N-{[2-[(2-bromophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine (example 78(b), 75 mg, 0.177 mmol), 2-methoxyphenylboronic acid (26.9 mg, 0.177 mmol), potassium carbonate (73.3 mg, 0.530 mmol), and tetrakis(triphenylphosphine)palladium (0) (6.13 mg, 5.30 μmol) in 1,4-Dioxane (1.5 ml) and Water (0.500 ml). The mixture was irradiated at 100° C. for 20 minutes. The reaction mixture was diluted with water (5 ml), acidified with 1N HCl (2 ml), and extracted with ethyl acetate (20 ml). The organic phase was dried over MgSO4, filtered, and solvents removed under reduced pressure. The crude residue was purified by HPLC chromatography (ODS silica, gradient 10-75% acetonitrile/water (0.1% TFA)) to afford the title compound N-[(5-hydroxy-6-(1-methylethyl)-2-{[2′-(methyloxy)-2-biphenylyl]methyl}-3-oxo-2,3-dihydro-4-pyridazinyl)carbonyl]glycine (40 mg, 0.088 mmol, 49.6% yield) as a white powder. 1H NMR (400 MHz, DMSO-d6) d ppm 15.80 (s, 1H), 12.99 (br. s., 1H), 10.09 (t, J=4.93 Hz, 1 H), 7.26-7.39 (m, 3H), 7.04-7.19 (m, 4H), 6.98 (td, J=7.45, 0.76 Hz, 1H), 5.00-5.16 (m, rotomers, 2H), 4.06 (d, J=5.81 Hz, 2H), 3.74 (s, 3H), 3.08 (m, 1H), 1.03-1.13 (m, rotomers, 6H). MS (ES+) m/e 452 [M+H]+.

Workup

  1. customThe mixture was irradiated at 100° C. for 20 minutes
  2. extractionextracted with ethyl acetate (20 ml)
  3. dry with materialThe organic phase was dried over MgSO4
  4. filtrationfiltered
  5. customsolvents removed under reduced pressure
  6. customThe crude residue was purified by HPLC chromatography (ODS silica, gradient 10-75% acetonitrile/water (0.1% TFA))

Sources & evidence

ORD record
ord-854941c3c1f94267b1e3236cf12952c3
Source dataset
uspto-grants-2013_11
Patent number
USRE044613E1

Reaction notes

Loading…